BCL2 and breast carcinoma: Also, Meslin et al. showed that PrPc expression is regulated by Bcl-2 expression in human breast cancer cells and suggested that depleting PrPc facilitates Bax activity by inhibiting Bcl-2 expression, thereby increasing sensitization of breast cancer cells to TRAIL treatment [38].